A recent study published in JAMA Network Open on 24 October reveals a significant rise in the absolute concentrations of fentanyl, methamphetamine, and cocaine in urine specimens across the United States between 2013 and 2023. Conducted by researchers from Johns Hopkins University, the analysis included 921,931 unique urine drug testing samples.

The study found that the adjusted concentration of fentanyl surged from 4.61 ng/mg creatinine in 2013 to 38.23 ng/mg in 2023. Methamphetamine levels increased from 665.27 ng/mg to 3,461.59 ng/mg, while cocaine concentrations rose from 559.71 ng/mg to 1,122.23 ng/mg over the same period. Interestingly, heroin concentration decreased from 146.59 ng/mg to 58.36 ng/mg in 2023.

These findings underscore a fundamental shift in drug exposure and the illicit drug supply, highlighting the need for enhanced surveillance initiatives and accelerated treatment efforts for individuals exposed to illicitly manufactured fentanyl and stimulants. The study’s authors emphasise the importance of addressing these changes to better manage the evolving landscape of substance use in the United States. This aligns with reports from the CDC, which note that fentanyl and its analogues have significantly contributed to the rise in U.S. drug overdose deaths. Additionally, experts have pointed out that the dangerous mix of stimulants like cocaine and methamphetamines with fentanyl is driving a new wave of the opioid epidemic.

This study highlights the growing risks linked to substance use in the U.S., with a sharp rise in the concentration of potent drugs like fentanyl and stimulants. Experts are urging more focus on tracking these dangerous trends and taking action to address the increasing threat posed by stronger, illicit substances entering the market.  As noted by the DEA, the potency and low cost of fentanyl have led to its widespread mixing with other drugs, including heroin, methamphetamine, and cocaine.

Source: Medical X Press